Group 1 - Wanhua Chemical's Yantai Industrial Park's ethylene unit has completed a technical upgrade and resumed production, achieving flexible feedstock switching between ethane and propane, enhancing competitiveness in the petrochemical industry [1] - United Water has won a long-term operation contract for municipal wastewater treatment in Saudi Arabia, with an estimated total investment of approximately 378 million RMB over a 15-year cooperation period [2] - Minsheng Health plans to invest 98 million RMB to establish a fund focused on the health industry, contributing 49% of the total fund size of 200 million RMB [3] Group 2 - Jialitu's shareholder, Anle Group, plans to reduce its stake by up to 3% of the company's total shares [4] - Laiyifen's controlling shareholder intends to reduce its stake by no more than 3% of the total shares [5] - Taifu Pump's actual controller's concerted action party plans to reduce its stake by up to 0.535% [7] Group 3 - Vanke A's executive vice president, Yu Liang, has resigned due to retirement [8] - Tian Sheng New Materials has suspended trading due to a potential change in control involving its largest shareholder [10] - Taisun Wind Power is in the early stages of business layout in the commercial aerospace sector [11] Group 4 - Lushin Investment holds only 0.89% equity in Blue Arrow Aerospace, indicating minimal impact on its financial status [12] - Huibo Pu's controlling shareholder is planning a change in control, leading to stock suspension [13] - Tubaobao's subsidiary is selling a stake in Daziran Home and acquiring specific equity for 4 billion RMB [14] Group 5 - Xingchen Technology plans to repurchase shares worth between 60 million and 120 million RMB for employee stock ownership plans [15] - Pulite expects no large-scale orders for its LCP film products in the brain-computer interface sector in the short term [16] - Rijiu Optoelectronics plans to raise up to 800 million RMB through a private placement for a functional film project [17] Group 6 - Yingqu Technology forecasts a net profit increase of 114.69% to 162.4% in 2025, with expected revenue growth of 13% to 18% [19] - Shanda Electric has won a project from Southern Power Grid worth approximately 13.43 million RMB [20] - Changhong Technology's subsidiary has secured over half of a major semiconductor customer's procurement share, amounting to over 10 million RMB [21] Group 7 - Pairui Co. has signed a framework agreement for bulk procurement of IGBT chips, with projected orders totaling approximately 1.74 billion RMB [22] - Aimeike has received a drug registration certificate for its exclusive distribution of injectable botulinum toxin products in China [23] - Quanyin High-Tech's stock will resume trading after a takeover offer from Zhongzhong Group, which now holds 40.51% of the company [24] Group 8 - Hailiang Co. has decided to suspend its investment in Jinlong Group due to significant external changes [25] - Quanxin Co. plans to issue convertible bonds to raise up to 312 million RMB for aviation communication projects [26] - Kangtai Bio's clinical trial application for a combined vaccine has been accepted by the National Medical Products Administration [27] Group 9 - Huaxia Happiness expects to report a net loss for 2025, with losses projected to exceed the previous year's audited net assets [28] - Xianju Pharmaceutical has received a drug registration certificate for Betamethasone Sodium Phosphate Injection [29] - Huaxia Happiness's controlling shareholder is involved in arbitration with a claim amount of approximately 6.4 billion RMB [30] Group 10 - Shaoneng Co. has launched its smart control center project, with an investment of 8.7 million RMB [31] - Jiangshun Technology is planning to establish an investment fund with professional institutions, with details still under discussion [32] - Beifang Changlong intends to acquire 51% of Shunyi Technology, which may constitute a major asset restructuring [33] Group 11 - Guoji Heavy Industry's revenue from "controlled nuclear fusion" products is currently negligible [34] - Hongrun Construction's shareholder plans to reduce its stake by up to 0.12% [35] - Puni Testing expects a net loss of 200 to 250 million RMB for 2025, although this represents an improvement from the previous year's loss [36] Group 12 - Kede Education's controlling shareholder is planning a change in control through a share transfer agreement [38] - Zhongwei Company’s major shareholder plans to reduce its stake by up to 2% [39] - Tongcheng New Materials is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange [40] Group 13 - ST Jianyi's shareholder plans to reduce its stake by up to 1.23% [41]

（编辑 丛可心） 证券日报网讯 1月8日，仙琚制药发布公告称，公司近日获国家药监局核准签发倍他米松磷酸钠注射液 《药品注册证书》，规格1ml：4mg（按C₂₂H₂₉FO₅计），属化学药品3类，用于需糖皮质激素治疗疾 病，已视同通过一致性评价，将丰富产品线。 ...

智通财经APP讯，仙琚制药(002332.SZ)公告，公司近日收到国家药品监督管理局核准签发的关于倍他米 松磷酸钠注射液的《药品注册证书》，公司倍他米松磷酸钠注射液被批准注册。倍他米松磷酸钠注射液 主要用于需要使用糖皮质激素治疗的疾病。 ...

格隆汇1月8日丨仙琚制药(002332.SZ)公布，近日收到国家药品监督管理局核准签发的关于倍他米松磷 酸钠注射液的《药品注册证书》（证书编号：2026S00006），公司倍他米松磷酸钠注射液被批准注 册。倍他米松磷酸钠注射液，规格1ml：4mg（按C₂₂H₂₉FO₅计），参比制剂为欧盟上市的倍他米松磷酸 钠注射液，商品名Celestone®。倍他米松磷酸钠注射液最早由先灵葆雅公司开发,持证商最终变更为 Organon公司。倍他米松磷酸钠注射液主要用于需要使用糖皮质激素治疗的疾病。Organon公司的倍他米 松磷酸钠注射液已在比利时、瑞典、荷兰、德国、法国、波兰等多个国家上市。 ...

仙琚制药公告称，近日收到国家药监局核准签发的倍他米松磷酸钠注射液《药品注册证书》。该药品规 格为1ml：4mg（按C₂₂H₂₉FO₅计），注册分类为化学药品3类。它主要用于糖皮质激素治疗相关疾病， 原研药已在多国上市。此次获批有利于丰富公司产品线、提升竞争力。但药品研发、生产和销售受政 策、市场等因素影响存在不确定性，提醒投资者注意风险。 ...

Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) announced that its subsidiaries, Tianjin Peace Pharmaceutical Co., Ltd. and Hubei Tian Pharmaceutical Co., Ltd., participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1 - The subsidiaries involved in the procurement are Tianjin Peace Pharmaceutical and Hubei Tian Pharmaceutical [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1]

Core Viewpoint - The company announced that its subsidiaries participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1: Procurement Participation - The subsidiaries of the company, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd. and Hubei Tianjin Pharmaceutical Co., Ltd., are involved in the national centralized drug procurement [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1] Group 2: Financial Impact - The total projected sales revenue from the selected products for the year 2024 is approximately 95.16 million yuan, accounting for 2.96% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue from these products is approximately 22.08 million yuan, representing 0.99% of the company's revenue for that period [1]

Core Viewpoint - 九州通 is undergoing a strategic transformation towards light asset operations and aims to become a dual-listed company on A-shares and public REITs, enhancing its market position in the biopharmaceutical industry [1][2]. Group 1: Strategic Transformation - 九州通 is focusing on a "three new and two modernization" strategy in 2024, achieving significant results in new products, new retail, new medical services, digitalization, and real estate securitization [2]. - The company has established a multi-level real estate equity capital operation platform, marking its transition from heavy assets to light assets [3]. Group 2: Financial Performance - In 2024, 九州通's total revenue reached 151.81 billion yuan, a year-on-year increase of 2.58%, while net profit attributable to shareholders was 2.507 billion yuan, up 39.88% [2]. - In Q1 2025, the company reported revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, reflecting an 80.38% growth [2]. Group 3: Product Pipeline Expansion - 九州通's product pipeline is expanding with the approval of "Betamethasone Sodium Phosphate Injection," which is expected to enhance market share and strengthen the company's competitive position in the injection product market [1][4]. - The company achieved sales revenue of 3.007 billion yuan from its self-produced and OEM pharmaceutical business in 2024, marking a 21.49% increase [5]. Group 4: Research and Development - 九州通's R&D investment in 2024 was 346 million yuan, reflecting a year-on-year growth of 24.32% [2].

Group 1 - Yara International's supervisor Peng Zhiyun is under investigation for insider trading, which is unrelated to the company's daily operations [2] - The company is operating normally despite the investigation, and Peng has applied to resign from his position [2] Group 2 - Fulin Precision's subsidiary Jiangxi Shenghua signed a supplementary agreement with CATL to increase production capacity to 160,000 tons/year in Jiangxi and 200,000 tons/year in Sichuan [3] - The agreement ensures that CATL will prioritize its demand from Jiangxi Shenghua and commit to purchasing at least 80% of the promised capacity annually [3] - This partnership is expected to enhance the competitiveness and sustainability of Fulin Precision's lithium iron phosphate business [3] Group 3 - Zai Jian Pharmaceutical signed an exclusive market promotion service agreement for recombinant human thyroid-stimulating hormone injection with Merck's Swiss subsidiary, Ares Trading S.A. [3] - The agreement includes a maximum authorization fee of RMB 250 million, with an initial payment of RMB 50 million due within 30 working days after the agreement takes effect [3] - The product is currently in the drug registration application stage [3] Group 4 - Wenta Technology announced that its major shareholder, Wuxi Guolian Integrated Circuit Investment Center, plans to reduce its stake by up to 3%, equating to 37.34 million shares [4] - The reduction will occur between June 27, 2025, and September 26, 2025 [4] Group 5 - Sanofi Guojian's application for a new drug listing for a recombinant anti-IL-1β humanized monoclonal antibody injection has been accepted by the National Medical Products Administration [5] - The drug is intended for the treatment of acute gouty arthritis and has achieved primary efficacy endpoints in Phase III clinical trials [5] Group 6 - Shuyou Shen's product STSP-0601 has been included in the priority review list by the National Medical Products Administration [6] - The product is a Class 1 therapeutic biological product approved for clinical trials for hemophilia A or B patients [7] Group 7 - Ningbo Port expects to complete a container throughput of 4.53 million TEUs in May, representing a year-on-year increase of 7.1% [8] - Wens Foodstuff's pig sales revenue increased by 14.23% year-on-year in May [8] - Dongfeng Motor's cumulative vehicle sales from January to May were 59,859 units, a decrease of 14.45% year-on-year [8]

Core Viewpoint - Tianjin Pharmaceutical Industry is recognized as a leading domestic manufacturer of steroid hormone drugs and a global leader in amino acid raw materials, showcasing its advanced position and demonstration effect in the industry for the year 2024 [1] Product Matrix - The company has a diverse product matrix with over 70 types of raw materials, including dexamethasone series, prednisone series, methylprednisolone series, betamethasone series, and amino acids, as well as more than 10 dosage forms such as injections, ointments, and tablets, catering to various patient treatment needs [2] R&D Innovation - In recent years, the company has significantly enhanced its product R&D and scientific research system, focusing on steroid hormones and amino acids, and implementing a "raw materials + formulations" full industry chain layout, with R&D investment reaching 248 million yuan in 2024, accounting for 7.7% of revenue, reflecting its strong R&D capabilities [3] Dual-Track Strategy - The company employs a dual-track strategy of "innovation line" and "generic line" to accelerate the new drug approval process, with 11 specifications of 10 products recently receiving approval, including the first domestic approval for a specific injection by its subsidiary [4] Market Performance - Among its products, the injection of isopropyl methochloride has shown strong market performance, with sales increasing from 756 million yuan in 2022 to 821 million yuan in 2023, and is expected to expand further due to its inclusion in the national medical insurance [5] - The inhalation solution of acetylcysteine is also a national medical insurance drug, with significant market potential in treating respiratory diseases, indicating a stable growth outlook as the patient population expands [5] Future Outlook - The company plans to continue its commitment to innovation, increasing investment in technology R&D, and focusing on new product development and consistency evaluation to provide high-quality, efficient drugs for patients and deliver substantial value returns to shareholders [6]